|

IBI363 Clinical Trials

7 actively recruiting trials across 2 locations

Also known as: IBI325, Lenvatinib

Pipeline

Phase 1: 1Phase 2: 4Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Innovent Biologics (Suzhou) Co. Ltd.4
  • Xiangdong Cheng1
  • Hunan Province Tumor Hospital1
  • Fortvita Biologics (USA)Inc.1

Indications

  • Cancer7
  • Melanoma3
  • Lung Cancer3
  • Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer1
  • IBI363 + Chemotherapy1

Other5 trials

A Study of IBI363 in Subjects With Advanced Melanoma
Phase 2
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Phase 2
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Phase 1
The Efficacy and Safety of IBI363 in Solid Tumors
Phase 1/2

Jonesboro, Arkansas1 trial

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

St. Bernards Healthcare

Phase 3

San Francisco, California1 trial

A Study of IBI363 in Subjects with Advanced Solid Malignancies

University of California, San Francisco (UCSF)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.